Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Letrozole ISM
- Development stage
- Unknown
- Lead developer
- Rovi
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Letrozole ISM (ROVI-2815) is a long-acting injectable formulation of the aromatase inhibitor letrozole, developed by Rovi using its proprietary In Situ Microparticles (ISM®) technology. The ISM® platform consists of a two-syringe system that, when mixed and injected intramuscularly, forms a solid or semi-solid matrix in the muscle tissue for controlled drug release. This formulation is intended for the treatment of hormone-dependent breast cancer, aiming to provide therapeutic levels of letrozole over several weeks or months, thereby improving patient compliance and potentially therapeutic outcomes compared to the standard daily oral dose. The project for its development is often referred to internally and in R&D grants as the LAISOLID project.
- Other names
- LAISOLIDLetrozole ISM-ROVI
02
Targets
CYP19A1 (Aromatase)
Beyond the preview
Go deeper on Letrozole ISM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Letrozole ISM.